Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antisense oligonucleotide therapy for urologic tumors.

Ingo Kausch1, Andreas Böhle

  • 1Department of Urology, Medical University of Lübeck, Ratzeburger Allee 160, Germany.

Current Urology Reports
|January 23, 2003
PubMed
Summary

Antisense oligonucleotides are revolutionizing cancer treatment, moving from labs to clinics. This review covers their use in treating urologic tumors, offering new hope for patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knowledge Gaps and Barriers to Care in Men with Postprostatectomy Incontinence: Evidence from the German ProKontinenz Trial.

European urology open science·2026
Same author

[Evaluation of a prostate cancer aftercare app from the patient perspective: A qualitative study].

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen·2022
Same author

International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer.

European urology·2021
Same author

Oncoprotein 18 is necessary for malignant cell proliferation in bladder cancer cells and serves as a G3-specific non-invasive diagnostic marker candidate in urinary RNA.

PloS one·2020
Same author

Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer.

European urology focus·2017
Same author

Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.

European urology·2016

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Oncology

Background:

  • Antisense oligonucleotide (ASO) technology enables targeted gene expression modulation.
  • ASO therapeutics have progressed from research to clinical application, with one drug approved.
  • ASOs are being explored for various diseases, including urologic cancers.

Purpose of the Study:

  • To provide a comprehensive overview of current preclinical and clinical antisense oligonucleotide strategies.
  • To highlight the application of ASOs in the treatment of urologic tumors.
  • To discuss the therapeutic potential of ASOs targeting proliferation and apoptosis in cancer.

Main Methods:

  • Review of existing preclinical and clinical studies on antisense oligonucleotides for urologic tumors.
  • Analysis of ASO mechanisms targeting proliferation and apoptosis-related genes.
  • Synthesis of current research trends and future directions in ASO therapy.

Main Results:

  • Antisense technology has demonstrated success in drug development, with clinical trials underway for urologic malignancies.
  • ASO compounds are being investigated for their efficacy against proliferation and apoptosis pathways in cancer cells.
  • Numerous novel gene targets are under evaluation in preclinical studies for ASO-based cancer therapy.

Conclusions:

  • Antisense oligonucleotides represent a promising therapeutic modality for urologic tumors.
  • Ongoing research and clinical trials are expanding the role of ASOs in oncology.
  • Targeted gene modulation with ASOs offers a viable strategy for future cancer treatments.

Related Experiment Videos